Sign Out
Breast Cancer: Metastatic Breast Cancer (MBC): Kadcyla, as a single agent, is indicated for the treatment of patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who have received prior treatment with trastuzumab and a taxane.
Early Breast Cancer (EBC): Kadcyla, as a single agent, is indicated for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual disease, after pre-operative systemic treatment that included HER2 targeted therapy.
Continue with Google